抗体靶向溶栓剂。

Antibody-targeted thrombolytic agents.

作者信息

Haber E, Quertermous T, Matsueda G R, Runge M S, Bode C

机构信息

Cardiac Unit, Massachusetts General Hospital, Boston 02114.

出版信息

Jpn Circ J. 1990 Apr;54(4):345-53. doi: 10.1253/jcj.54.345.

DOI:10.1253/jcj.54.345

PMID:2204740

Abstract

Plasminogen activator therapy for acute myocardial infarction has become standard medical practice. Bleeding complications, however, limit the utility of the currently available agents. This article reviews how the tools of immunology, molecular biology and protein engineering are being used to develop safer and more effective plasminogen activators.

摘要

纤溶酶原激活剂疗法用于急性心肌梗死已成为标准医疗实践。然而，出血并发症限制了当前可用药物的效用。本文综述了免疫学、分子生物学和蛋白质工程工具如何被用于开发更安全、更有效的纤溶酶原激活剂。